Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer

NCT03877796 is registered in ClinicalTrials.gov with Allarity Therapeutics as lead sponsor.

NCT NCT03877796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03877796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer
Lead sponsor
Allarity Therapeutics
Phase
Observational
Overall status
Recruiting
Start date
April 11, 2019
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer